Jens Hasskarl

Given track record across multiple Cell & Gene Therapy Clinical Development programs in what is now Kymriah®, Breyanzi®, and Abecma®, with the most recent approvals of Breyanzi® in 2nd line DLBCL.

Prior Experience

Celgene/BMS

• Executive Medical Director, Program Lead Global Clinical Research and Development GCR&D CAR -T
• Head Europe Cellular Therapy Clinical Center of Expertise

Novartis

• Senior Global Clinical Leader, CTL019 Lymphoma
• A. i. Global Clinical Program Head, CTL019 Lymphoma

Academic Career

• Board certification in internal medicine, hematology
  and oncology
• Group leader at University Hospital Freiburg, Germany
• Venia legendi internal medicine and private lecturer

Education

• Postdoctoral fellow at Harvard Medical School, Boston, MA
• German Cancer Research Center, Heidelberg, Germany
• Medical Schools in Freiburg, Germany, Vienna, Austria, Heidelberg, Germany, and Harvard Medical School, Boston, MA, USA, Stipend of Biomedical Exchange Program (BMEP)